Vaccines & Disease · Influenza

Influenza: Quick Facts

6 min read
01

What is Influenza?

  • Influenza is a contagious respiratory illness caused by influenza viruses. The two main types of influenza viruses that spread among human beings are influenza A and B.
  • Influenza symptoms usually begin 1–4 days after infection, start suddenly, and include fever or chills, cough, sore throat, runny nose, body aches, headaches, and fatigue, with most cases improving within about a week, though severe infections can worsen over several days and progress to pneumonia and bronchitis.
  • It is important to remember that there are many respiratory infections, which cause influenza-like-illness (ILI) that mimic influenza but are caused by other types of viruses, such as rhinoviruses, coronaviruses, adenoviruses, respiratory syncytial virus (RSV), and parainfluenza viruses. Just because you have symptoms of influenza, does not necessariy mean you have influenza. In fact the majority of ILI every “flu season” is not caused by type A or B influenza. Only lab testing can confirm which type of virus is making you or your child sick.
  • People at increased risk for serious influenza type A or B complications include adults aged 65 years and older, children younger than 2 years, pregnant women, and people with chronic medical conditions such as asthma or other lung diseases, cancer, heart disease, diabetes, neurologic conditions, and blood disorders.
  • During the 2024–25 flu season, there were 38,960 lab-confirmed type A or B influenza hospitalizations. Among those hospitalized, 16.8% were admitted to ICU, 6.1% required mechanical ventilation, and 3.0% died, with the highest hospitalization rates in adults aged 75+.
  • For uncomplicated influenza, treatment usually includes rest, fluids, and over-the-counter medications. Some doctors recommend that severe cases be treated with antivirals, such as oseltamivir, zanamivir, peramivir, or baloxavir. Depending upon the individual, these medications may or may not help shorten illness and reduce complications.
  • Vaccinated individuals experience varying levels of protection from influenza each season, depending how closely the vaccine matches the influenza viruses circulating in the community. When the match is poor, the vaccine provides limited or no protection against certain strains. For the past 21 years, the CDC has estimated influenza vaccine effectiveness during the “flu season” to be between 10 and 60 percent, with a less than 50 percent effectiveness for the majority of the seasons.
  • Since many people with influenza either recover at home without seeking medical care or are never tested for influenza, official case counts underestimate the true number of infections, which is why the U.S. Centers for Disease Control and Prevention (CDC) uses statistical models to estimate how widespread the illness is every year.
02

The Influenza Vaccine

  • In the United States, influenza vaccines include inactivated, recombinant, and live attenuated nasal spray vaccines, with some formulations designed as high-dose, adjuvanted, cell-based, or jet-injector administered.
  • According to the CDC’s ACIP recommendations, every person aged six months and older, who does not have contraindications, should receive one flu shot every year, with adults aged 65 years and older recommended to receive a high-dose, adjuvanted, or recombinant influenza vaccine when available.
  • The CDC recommends that some children between six months and eight years old receive two flu shots in one season if they are being vaccinated for the first time, or have previously received only one dose, or have an unknown vaccination history, with the second dose given at least four weeks after the first.
  • Influenza vaccines were first developed in the 1940s, with the first U.S. influenza vaccine licensed in 1945. Over time, the vaccines evolved from whole-virus formulations to split-virus, subunit, live attenuated, cell-based, and recombinant vaccines.
  • Influenza vaccines are known to be marginally effective and have waning immunity over the course of a season, as well as reduced effectiveness when circulating influenza viruses differ from strains included in the vaccine (strain mismatch). Influenza vaccines have been shown to offer varying degress of protection and lessening of symptoms depending upon the product used and individual responses, but the vaccine does not reliably prevent infection and/ or transmission of influenza.
  • There are nine influenza vaccines licensed for used in the United States for the 2025-26 flu season:
    1. FluMist (MedImmune, LLC/AstraZeneca)
    2. Afluria (Seqirus Pty. Ltd)
    3. Fluad® Trivalent (Seqirus, Inc.)
    4. Fluarix® Trivalent (GlaxoSmithKline Biologicals)
    5. Flucelvax® Trivalent (Seqirus, Inc.)
    6. FLULAVAL® Trivalent (ID Biomedical Corporation of Quebec)
    7. Flublok® Trivalent (Protein Sciences Corporation)
    8. Fluzone® Trivalent (Sanofi Pasteur, Inc.)
    9. Fluzone® High-Dose Trivalent (Sanofi Pasteur, Inc.)
03

Natural Immunity vs Vaccine Immunity

  • After a person recovers from influenza, his or her immune system develops protection against that specific strain of the influenza virus. However, influenza viruses change frequently through antigenic drift, which reduces long-term protection and allows new strains to bypass existing immunity and cause reinfection in future seasons.
  • Influenza vaccine effectiveness varies each season due to virus strain match, age, health, and waning immunity, so people may still get influenza after getting a flu shot.
  • The CDC conducts annual influenza vaccine effectiveness studies comparing laboratory-confirmed influenza cases in vaccinated and unvaccinated people. These studies show the effectiveness varies by season and virus subtype, with influenza vaccine effectiveness less than 50 percent for the past two decades.
04

Vaccine Risks & Adverse Events

  • Manufacturers of different influenza vaccines list specific adverse events in FDA-approved package information inserts linked above, but the most common adverse reactions are soreness at the injection site, low-grade fever, headache, muscle aches, fatigue, and sometimes nasal congestion or sore throat.
  • Manufacturers of different influenza vaccines list specific serious adverse events in FDA-approved package inserts linked above, but the most consistently documented rare serious risks across products include anaphylaxis, fainting (syncope), Guillain–Barré syndrome (weakness, numbness, paralysis) and other types of neurological and immune system disorders that have been reported after receipt of flu shots.
  • These and other serious adverse reactions are documented in the medical literature to occur following receipt of influenza vaccines.
  • Influenza vaccine injuries have been compensated by the U.S. government under the Vaccine Injury Compensation Program (VICP) created by the National Childhood Vaccine Injury Act of 1986. As of March 2026, claimants citing influenza vaccine injuries have been the most compensated in the VICP.
05

Individual Susceptibility

The Institute of Medicine, National Academy of Sciences, has acknowledged in published reports that:

  • Individuals vary in susceptibility to vaccine reactions due to due to differences in biological, genetic, epigenetic and environmental factors.
  • Doctors and other medical workers administering vaccines often do not know how to predict who will be harmed before vaccination due to gaps in scientific knowledge about who is genetically or otherwise biologically at high risk for suffering harm.
  • A previous vaccine reaction can raise the risks for a reaction after another dose of vaccine.
  • It is very important to consider your health or your child’s health and review your own and your family’s health history for the presence of autoimmune, allergic, neurological and metabolic disorders when making a decision about the timing of vaccination or whether or not to vaccinate.
06

Your Right to Informed Consent

Nobody can guarantee in advance that your child will not be injured by a vaccine or an infectious disease. NVIC supports your legal right to have full information about the risks of a disease and the risks of a vaccine and the freedom to exercise voluntary, informed consent to vaccination without being coerced or sanctioned for the decision made.

NVIC supports the ending of vaccine mandates in every state.

Key Takeaways

  1. Influenza poses the greatest risk to older adults and individuals with chronic medical conditions, who are more likely to experience severe complications, hospitalization, and death.
  2. Most of the respiratory infections which cause influenza like illness during the “flu season” are not caused by type A or B infuenza but are caused by other viruses, and only lab testing can determine which virus is causing symptoms.
  3. Influenza vaccines are associated with both mild side effects, such as fatigue, muscle aches, low fever, sore throat, and headache, while rare serious adverse events such as anaphylaxis, Guillain–Barré syndrome and other types of brain and immune system disorders have been reported by manufacturers and in studies published in the medical literature.
  4. The U.S government has awarded compensation to children and adults injured by influenza vaccines, with influenza vaccine injury claims the leading and most compensated claims in the Vaccine Injury Compensation Program (VICP).
  5. Immunity to influenza, whether from natural infection or vaccination, can be limited because influenza viruses frequently change through antigenic drift. Natural immunity to a particular influenza strain may last longer than vaccine acquired immunity, but both wane over time and neither prior infection nor vaccination is guaranteed to prevent future influenza infections.
  6. You have the right to exercise informed consent to medical risk taking and should have the freedom to choose whether or not to accept a vaccine risk for your child without being sanctioned for the choice you make.
Bottom Line
Vaccination is not a one-size-fits-all medical intervention. Before you take a risk, find out what it is.

Search for Vaccine Reactions

NVIC hosts MedAlerts, a powerful and user-friendly search engine of the federal Vaccine Adverse Events Reporting System (VAERS). MedAlerts makes it easy to search for vaccine reaction reports to VAERS, including immediate symptoms and long term health outcomes.

IMPORTANT NOTE: NVIC encourages you to become fully informed about Influenza and the Influenza vaccines, including reviewing the References at the end of this page and reading all sections in the Table of Contents. You will find many useful links and resources with more detailed information, such as the manufacturer product information inserts, that help you make a decision about vaccination. You are also encouraged to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information provided by NVIC is for educational purposes only and is not intended as medical advice.

Select disease / vaccine